Article date: April 2019
By: Zhang Mao, Xu Han, Dahong Chen, Youwei Xu, Lina Xu, Lianhong Yin, Huijun Sun, Yan Qi, Lingling Fang, Kexin Liu, Jinyong Peng in Volume 176, Issue 7, pages 919-937
Background and purpose
Dioscin shows potent effects against cancers. We aimed to elucidate its pharmacological effects and mechanisms of action on hepatocellular carcinoma (HCC) in vivo and in vitro.
Experimental approach
Effects of dioscin were investigated in SMMC7721 and HepG2 cells, diethylnitrosamine‐induced primary liver cancer in rats, and cell xenografts in nude mice. Isobaric tags for relative and absolution quantitation (iTRAQ)‐based proteomics was used to find dioscin's targets and investigate its mechanism.
Key results
In SMMC7721 and HepG2 cells dioscin markedly inhibited cell proliferation and migration, induced apoptosis, autophagy, and DNA damage. It inhibited DEN‐induced primary liver cancer in rats, markedly changed body weights and restored levels of α fetoprotein, alanine transaminase, aspartate transaminase, γ‐glutamyltransferase, alkaline phosphatase, and Ki67. It also inhibited growth of xenografts in mice. In SMMC7721 cells, 191 differentially expressed proteins were found after dioscin, based on iTRAQ‐based assay. TP53‐inducible glycolysis and apoptosis regulator (TIGAR) was identified as being significantly down‐regulated by dioscin. Dioscin induced cell apoptosis, autophagy, and DNA damage via increasing expression levels of p53, cleaved PARP, Bax, cleaved caspase‐3/9, Beclin‐1, and LC3 and suppressing those of Bcl‐2, p‐Akt, p‐mammalian target of rapamycin (mTOR), CDK5, p‐ataxia telangiectasia‐mutated gene (ATM). The transfection of TIGAR siRNA into SMMC7721 cells and xenografts in nude mice further confirmed that the potent activity of dioscin against HCC is evoked by adjusting TIGAR‐mediated inhibition of p53, Akt/mTOR, and CDK5/ATM pathways.
Conclusions and implications
The data suggest that dioscin has potential as a therapeutic, and TIGAR as a drug target for treating HCC.
DOI: 10.1111/bph.14594
View this article